Q32 Bio Inc. (QTTB)
1.80
-0.10 (-5.26%)
At close: Mar 13, 2025, 1:39 PM
Q32 Bio Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
| Revenue | 1.16M | 6.65M | 33.97M | 2.7M | 1.67M | 5.32M | n/a | n/a |
| Cost of Revenue | 578K | 2.6M | 9.54M | n/a | n/a | n/a | 684.21K | 239.8K |
| Gross Profit | 578K | 4.05M | 24.43M | 2.7M | 1.67M | 5.32M | -684.21K | -239.8K |
| Operating Income | -92.1M | -39.23M | -36.69M | -130.26M | -109.94M | -59.93M | -29.66M | -10M |
| Interest Income | 5.58M | n/a | n/a | 1.57M | 6.03M | 4.35M | 542.63K | 24.2K |
| Pretax Income | -87.08M | -42.75M | -37.02M | -128.69M | -103.92M | -55.58M | -29.99M | -8.05M |
| Net Income | -112.96M | -42.81M | -37.56M | -128.69M | -103.92M | -55.58M | -29.99M | -8.05M |
| Selling & General & Admin | 30.68M | 10.06M | 6.76M | 23.67M | 15.89M | 16.01M | 7.6M | 4.07M |
| Research & Development | 62M | 35.81M | 29.93M | 100.39M | 89.4M | 47.95M | 21.38M | 5.69M |
| Other Expenses | n/a | -1.12M | -324K | n/a | n/a | n/a | n/a | n/a |
| Operating Expenses | 92.68M | 45.88M | 36.69M | 124.06M | 105.29M | 63.96M | 28.97M | 9.76M |
| Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 93.26M | 45.88M | 36.69M | 132.97M | 111.61M | 65.25M | 29.66M | 10M |
| Income Tax | 25.88M | 62K | 547K | -1 | n/a | n/a | -4 | 2.00 |
| Shares Outstanding (Basic) | 3.21M | 3.19M | 3.07M | 2.55M | 2.34M | 1.59M | 2.08M | 2.08M |
| Shares Outstanding (Diluted) | 3.21M | 3.19M | 3.07M | 2.55M | 2.34M | 1.59M | 2.08M | 2.08M |
| EPS (Basic) | -35.16 | -13.42 | -12.23 | -50.46 | -44.41 | -35.04 | -14.42 | -3.87 |
| EPS (Diluted) | -35.16 | -13.42 | -12.23 | -50.46 | -44.41 | -35.04 | -14.42 | -3.87 |
| EBITDA | -86.5M | -38.85M | -86.22M | -121.36M | -103.63M | -58.64M | -29.31M | -7.81M |
| Depreciation & Amortization | 578K | 2.6M | 9.54M | 8.9M | 6.32M | 1.29M | 684.21K | 239.8K |